HK1152311A1 - Heteroaryl-substituted piperidines - Google Patents

Heteroaryl-substituted piperidines

Info

Publication number
HK1152311A1
HK1152311A1 HK11106516.9A HK11106516A HK1152311A1 HK 1152311 A1 HK1152311 A1 HK 1152311A1 HK 11106516 A HK11106516 A HK 11106516A HK 1152311 A1 HK1152311 A1 HK 1152311A1
Authority
HK
Hong Kong
Prior art keywords
heteroaryl
substituted piperidines
piperidines
substituted
Prior art date
Application number
HK11106516.9A
Other languages
English (en)
Inventor
Dirk Heimbach
Susanne Röhrig
Dirk Schneider
Ulrich Rester
Eckhard Bender
Mark Meininghaus
Katja Zimmermann
Dimitry Zubov
Anja Buchmüller
Degenfeld Georges Von
Christoph Gerdes
Michael Gerisch
Mark Jean Gnoth
Grande Yolanda Cancho
Kersten Matthias Gericke
Mario Jeske
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102007057718A external-priority patent/DE102007057718A1/de
Priority claimed from DE102008010221A external-priority patent/DE102008010221A1/de
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HK1152311A1 publication Critical patent/HK1152311A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK11106516.9A 2007-11-30 2011-06-23 Heteroaryl-substituted piperidines HK1152311A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007057718A DE102007057718A1 (de) 2007-11-30 2007-11-30 Heteroaryl-substituierte Piperidine
DE102008010221A DE102008010221A1 (de) 2008-02-20 2008-02-20 Heteroaryl-substituierte Piperidine
PCT/EP2008/009792 WO2009068214A2 (de) 2007-11-30 2008-11-20 Heteroaryl-substituierte piperidine

Publications (1)

Publication Number Publication Date
HK1152311A1 true HK1152311A1 (en) 2012-02-24

Family

ID=40580130

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106516.9A HK1152311A1 (en) 2007-11-30 2011-06-23 Heteroaryl-substituted piperidines

Country Status (20)

Country Link
US (2) US8119663B2 (da)
EP (1) EP2227466B1 (da)
JP (1) JP5450435B2 (da)
KR (1) KR20100114018A (da)
CN (1) CN101932577B (da)
AR (1) AR069417A1 (da)
AT (1) ATE506359T1 (da)
CA (1) CA2706991A1 (da)
CL (1) CL2008003473A1 (da)
DE (1) DE502008003324D1 (da)
DK (1) DK2227466T3 (da)
HK (1) HK1152311A1 (da)
HR (1) HRP20110510T1 (da)
PA (1) PA8805201A1 (da)
PE (1) PE20091026A1 (da)
PL (1) PL2227466T3 (da)
PT (1) PT2227466E (da)
TW (1) TW200936135A (da)
UY (1) UY31484A1 (da)
WO (1) WO2009068214A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022895A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022897A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
EP2585441A4 (en) * 2010-06-28 2013-10-09 Hetero Research Foundation PROCESS FOR OLMESARTAN MEDOXOMIL
MX2013000836A (es) 2010-07-22 2013-09-26 Zafgen Inc Compuestos triciclicos y metodos para elaborar y usar los mismos.
CN103370307B (zh) 2010-10-12 2016-05-25 扎夫根股份有限公司 磺酰胺化合物及其制备方法和使用方法
WO2012054510A1 (en) * 2010-10-19 2012-04-26 Comentis, Inc. Oxadiazole compounds which inhibit beta-secretase activity and methods of use thereof
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
CA2861390A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
EP2917197B1 (en) 2012-11-05 2019-06-05 Zafgen, Inc. Tricyclic compounds and methods of making and using same
MX2015005734A (es) 2012-11-05 2016-02-10 Zafgen Inc Metodos de tratamiento de enfermedades hepaticas.
WO2014071369A1 (en) 2012-11-05 2014-05-08 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
CN103965095A (zh) * 2013-02-04 2014-08-06 艾琪康医药科技（上海）有限公司 1-r1-3-r2-4-氟哌啶及其衍生物的制备方法
CN104341590A (zh) * 2013-08-01 2015-02-11 韩冰 一种树枝状高分子化合物及其制备和用途
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA951618B (en) * 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
DE69735710T2 (de) * 1996-02-13 2007-03-29 Abbott Laboratories, Abbott Park Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten
WO1997036873A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US6403612B2 (en) * 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
ATE425964T1 (de) * 2001-04-19 2009-04-15 Eisai R&D Man Co Ltd Cyclische amidinderivate
DE60216310T2 (de) * 2001-10-15 2007-06-21 Janssen Pharmaceutica N.V. Substituierte 4-phenyl-4-(1h-imidazol-2-yl)-piperidinderivate zur verringerung von ischämischer schädigung
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
JP2008504278A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
CA2589565A1 (en) 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
AU2005273986A1 (en) 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
DE102004045796A1 (de) * 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
WO2006051623A1 (ja) * 2004-11-09 2006-05-18 Eisai Co., Ltd. トロンビン受容体アンタゴニストを有効成分とするくも膜下出血に伴う血管攣縮の治療剤
EP1931652A2 (en) 2005-09-21 2008-06-18 Incyte Corporation Amido compounds and their use as pharmaceuticals
BRPI0707408A2 (pt) 2006-01-31 2011-05-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
WO2007101270A1 (en) 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007130898A1 (en) * 2006-05-01 2007-11-15 Incyte Corporation TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1

Also Published As

Publication number Publication date
WO2009068214A2 (de) 2009-06-04
WO2009068214A3 (de) 2009-08-20
EP2227466B1 (de) 2011-04-20
KR20100114018A (ko) 2010-10-22
ATE506359T1 (de) 2011-05-15
CN101932577B (zh) 2013-07-17
AR069417A1 (es) 2010-01-20
PT2227466E (pt) 2011-07-01
PA8805201A1 (es) 2010-02-12
EP2227466A2 (de) 2010-09-15
DE502008003324D1 (de) 2011-06-01
UY31484A1 (es) 2009-07-17
HRP20110510T1 (hr) 2011-08-31
CA2706991A1 (en) 2009-06-04
CL2008003473A1 (es) 2009-08-14
US8119663B2 (en) 2012-02-21
TW200936135A (en) 2009-09-01
US20090306139A1 (en) 2009-12-10
US20120214788A1 (en) 2012-08-23
PL2227466T3 (pl) 2011-09-30
JP5450435B2 (ja) 2014-03-26
JP2011504889A (ja) 2011-02-17
CN101932577A (zh) 2010-12-29
PE20091026A1 (es) 2009-07-26
DK2227466T3 (da) 2011-08-08

Similar Documents

Publication Publication Date Title
HK1152311A1 (en) Heteroaryl-substituted piperidines
DE602008005470D1 (en) Imidazopyridinone
AP2010005314A0 (en) Nanodispersian
GB0722995D0 (en) Completion arrangement
GB0701574D0 (en) Wave-dissipating block
ZA200905042B (en) Enrofloxacin-hexahydrate
GB0723387D0 (en) Improved dehumldifier
EP2134587A4 (en) INTERMEDIATE TRACTION BAR ARRANGEMENT
GB0700595D0 (en) Holecutter
GB2439468B (en) NeoGuard
DE602008004135D1 (en) Triphenylmethan- und xanthenpigmente
AU3646P (en) TAS300 Dianella tasmanica
AU3595P (en) Goldust Strobilanthes anisophyllus
AU3952P (en) FLOCHRDEF Chrysocephalum apiculatum
AU3702P (en) DarwinGold Dianella ensifolia
AU3642P (en) TAS100 Dianella tasmanica
AU3613P (en) LS005A01 Leucospermum cuneiforme
AU3606P (en) Jaywick xTriticosecale
GB0711472D0 (en) Block
HU0700147V0 (en) Block
AP2007004122A0 (en) Flashmecash
GB0700248D0 (en) Pro-tiler
AU320545S (en) Multi-opener
AU318847S (en) Cordless-multi-cutter
AU316644S (en) Bed - AP

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171120